Novartis Q2 Beats on Strong Drug Sales, but DeepValue Flags Premium Valuation and LOE Risks

What happened

Novartis reported Q2 2026 core operating profit that beat market expectations, driven by strong sales of cancer and multiple sclerosis drugs, as generic competition mounts on older products. The beat comes as the company navigates the loss of exclusivity on blockbuster heart drug Entresto, with generic erosion already visible, though priority brands like Kisqali, Kesimpta, and Pluvicto are growing strongly to offset the drag. Despite the positive earnings surprise, DeepValue's master report maintains a "Potential Sell" rating at $144, citing a 47% twelve-month rally that has left the stock trading at a ~19.5x P/E premium to peers, with limited upside beyond 3-4% yield. The report's base case sees the stock at $145 (45% probability), assuming priority brands balance Entresto's decline, but the bear case at $120 (30% probability) warns of accelerated generic erosion and underperformance of key growth assets. Management's guidance for 5-6% sales CAGR through 2030 and a return to 40%+ margins by 2029 is achievable, but the narrow margin of safety means any stumble in the concentration of growth drivers could trigger a re-rating.

Implication

Over 12-18 months, the premium multiple is vulnerable to any sign that Entresto erosion is accelerating or that new drug blockbusters are slowing. The 5-6% CAGR narrative is priced in; the risk/reward skews negative. Consider trimming on strength.

Thesis delta

The Q2 beat confirms near-term operational strength, but it does not change the core thesis that the stock is fully valued given looming LOE headwinds and concentration risks. The incremental positive from the earnings surprise is offset by the unchanged structural challenge of offsetting Entresto's decline with a narrow set of growth assets. No shift in the 'Potential Sell' stance; if anything, the beat may provide a better exit opportunity for those already positioned.